Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Hepato-Biliary

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

All‐cause mortality · people with hepatorenal syndrome

Terlipressin may leads to lower mortality compared with placebo or no intervention (low certainty).

1 finding from 1 review

Mortality (all‐cause) · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes mortality (All‐cause) compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.96 [0.88, 1.06]
474 participants
Very low